Phase change materials (PCMs) in the form of fibers or fibrous mats with exceptional thermal energy storage ability and tunable working temperature are of high interest to produce smart thermoregulating textiles, useful for increasing human thermal comfort while avoiding energy waste. Common organic PCMs suffer from instability in their molten state, which limits their applicability as highly performing fibrous systems. In this work, electrospun fibrous mats made of polyethylene oxide (PEO), a PCM with excellent thermal properties and biocompatibility, were fabricated and their shape instability in the molten state was improved through UV photo-crosslinking. The characterization aimed to assess the performance of these shape-stable electrospun mats as nanofibrous PCMs for thermal management applications. In addition to an enhanced resistance to water-based solvents, UV-cured electrospun PEO mats demonstrated a remarkable latent heat (≈112 J/g), maintained over 80 heating/cooling cycles across the phase change temperature. Moreover, their morphological stability above their melting point was demonstrated both macroscopically and microscopically, with the retention of the initial nanofibrous morphology. Tensile mechanical tests demonstrated that the UV crosslinking considerably enhanced the ultimate properties of the fibrous mat, with a five-fold increase in both the tensile strength (from 0.15 MPa to 0.74 MPa) and the strain at break (from 2.5% to 12.2%) compared to the uncrosslinked mat. In conclusion, the photo-crosslinked electrospun PEO material exhibited high thermal properties and good shape stability without displaying leakage; accordingly, in the proposed PCM system, the necessity for encapsulation or use of a supporting layer has been eliminated. Photo-crosslinking thus proved itself as an effective, fast, and environmentally friendly method to dramatically improve the shape-stability of nanofibrous PEO electrospun mats for smart thermoregulating textiles.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434372 | PMC |
http://dx.doi.org/10.3390/polym13172979 | DOI Listing |
J Clin Psychiatry
January 2025
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.
View Article and Find Full Text PDFJ Clin Psychiatry
January 2025
Division of Pharmacotherapy and Translational Science, College of Pharmacy, University of Texas at Austin, San Antonio, Texas.
To evaluate weight change with a combination of olanzapine and samidorphan (OLZ/SAM) versus olanzapine by pooling data across clinical studies. This study was an individual patient data (IPD) meta-analysis of clinical trial data. EMBASE, MEDLINE, and PsycInfo were searched for randomized clinical trials (≥12 weeks) in adults with schizophrenia or bipolar I disorder in which weight change from baseline was the primary or secondary end point.
View Article and Find Full Text PDFCent Eur J Public Health
December 2024
Department of Radiology, AGEL Hospital, Levoca, Slovak Republic.
Objectives: Many studies draw attention to the negative consequences of the pandemic or lockdown on the well-being and lifestyle of different sections of the population. This study considers whether changes occurred in dietary regime and level of physical activity during three periods - before the pandemic, during the lockdown, and during the present in older Slovak adults. We also investigate whether individual weights changed during the pandemic.
View Article and Find Full Text PDFClin Drug Investig
January 2025
Medical Science Department, Shionogi & Co., Ltd., Osaka, Japan.
Background: Anti-obesity medications are recommended for patients who do not achieve and maintain weight loss despite lifestyle interventions. S-309309 is a novel oral inhibitor of monoacylglycerol O-acyltransferase 2 being developed as a treatment for obesity.
Objective: The objective of the study was to investigate the safety, clinical pharmacology, pharmacokinetics and pharmacodynamic biomarker of S-309309.
Clin Cancer Res
January 2025
The Wistar Institute, Philadelphia, PA, United States.
Purpose: A first-in-human phase one study was conducted in nasopharyngeal carcinoma (NPC) patients to assess the safety and tolerability of VK-2019, a small molecule selective inhibitor of Epstein-Barr virus Nuclear Antigen 1 (EBNA1).
Patients And Methods: Pharmacokinetic and pharmacodynamic studies, including circulating tumor EBV DNA plasma levels, were performed. Twenty-three patients received VK-2019 orally once daily at doses ranging from 60 to 1800 mg using an accelerated titration design, with cohort expansion at 1800 mg.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!